Plain-English translation of NCT06241729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing whether artificial intelligence algorithms can predict which patients with diffuse large-cell B lymphoma (an aggressive blood cancer) will not respond well to standard treatment. If doctors can identify these patients early, they can switch to stronger or targeted treatments sooner, which may improve outcomes. This study will validate computer models that were shown to work in earlier research.
About one-third of patients with this type of lymphoma don't respond to standard treatment, which is a serious challenge. Currently, doctors don't have reliable tools to predict who these patients are upfront. By developing this prediction tool, doctors could start more aggressive or personalized therapies immediately rather than waiting to see if the first treatment works, potentially improving survival and reducing unnecessary side effects.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow researchers to collect and analyze information from your medical records — including your diagnosis, test results, and treatment details — to feed into the artificial intelligence models. You would not receive any special medication or undergo extra procedures beyond your regular cancer care. The study involves one center in Belgium and aims to enroll about 50 patients total.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
Belgium